丹益片联合普适泰片治疗慢性非细菌性前列腺炎的临床研究
|
摘要
目的探讨丹益片联合普适泰片治疗慢性非细菌性前列腺炎的临床疗效。方法选取2017年5月—2018年5月在平顶山煤业集团公司一矿职工医院治疗的慢性非细菌性前列腺炎患者94例,根据就诊号分为对照组(47例)和治疗组(47例)。对照组口服普适泰片,1片/次,2次/d;治疗组在对照组基础上口服丹益片,4/片,3次/d。两组患者均治疗4周。观察两组患者临床疗效,同时比较治疗前后两组患者IIEF-5和NIH-CPSI评分及尿流率和前列腺液中细胞因子水平。结果治疗后,对照组和治疗组临床有效率分别为80.85%和95.74%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者IIEF-5评分明显升高(P<0.05),NIH-CPSI评分均明显降低(P<0.05),且治疗组患者IIEF-5和NIH-CPSI评分明显优于对照组(P<0.05)。治疗后,两组患者最大尿流率和平均尿流率均明显升高(P<0.05),且治疗组患者最大尿流率和平均尿流率明显高于对照组(P<0.05)。治疗后,两组前列腺液中白细胞介素-2(IL-2)、IL-6、巨噬细胞炎性蛋白2(MIP-2)、结缔组织生长因子(CTGF)水平均显著降低(P<0.05),转化生长因子-β1(TGF-β1)水平显著升高(P<0.05),且治疗组上述细胞因子水平明显好于对照组(P<0.05)。结论丹益片联合普适泰片治疗慢性非细菌性前列腺炎可显著改善机体细胞因子水平,减轻患者临床不适症,提高尿流率。
Objective To investigate the clinical efficacy of Danyi Tablets combined with Prostat Tablets in treatment of chronic nonbacterial prostatitis. Methods Patients(94 cases) with chronic nonbacterial prostatitis in Pingdingshan Coal Group Corporation Yikuang Staff Hospital from May 2017 to May 2018 were divided into control(47 cases) and treatment(47 cases) groups based on visiting number. Patients in the control group were po administered with Prostat Tablets, 1 tablet/time, twice daily. Patients in the treatment group were po administered with Danyi Tablets on the basis of the control group, 4 tablets/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the IIEF-5 and NIH-CPSI scores, the urine flow rate and the cytokine levels of prostatic fluid in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 80.85% and 95.74% respectively, and there were differences between two groups(P < 0.05). After treatment, the IIEF-5 scores in two groups were significantly increased(P < 0.05),but NIH-CPSI scores were significantly decreased(P < 0.05), and these scores in the treatment group were significantly better than those in the control group(P < 0.05). After treatment, the maximum urine flow rate and average urinary flow rate in two groups was significantly increased(P < 0.05), and which in the treatment group was significantly higher than that in the control group(P < 0.05).After treatment, the IL-2, IL-6, MIP-2 and CTGF levels of prostatic fluid in two groups were significantly decreased(P < 0.05), but TGF-β1 levels were significantly decreased(P < 0.05), and these cytokine levels of prostatic fluid in the treatment group were significantly better than those in the control group(P < 0.05). Conclusion Danyi Tablets combined with Prostat Tablets in treatment of chronic nonbacterial prostatitis can significantly improve the cytokine levels and the clinical symptoms of patients, increase the urine flow rate.
Objective To investigate the clinical efficacy of Danyi Tablets combined with Prostat Tablets in treatment of chronic nonbacterial prostatitis. Methods Patients(94 cases) with chronic nonbacterial prostatitis in Pingdingshan Coal Group Corporation Yikuang Staff Hospital from May 2017 to May 2018 were divided into control(47 cases) and treatment(47 cases) groups based on visiting number. Patients in the control group were po administered with Prostat Tablets, 1 tablet/time, twice daily. Patients in the treatment group were po administered with Danyi Tablets on the basis of the control group, 4 tablets/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the IIEF-5 and NIH-CPSI scores, the urine flow rate and the cytokine levels of prostatic fluid in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 80.85% and 95.74% respectively, and there were differences between two groups(P < 0.05). After treatment, the IIEF-5 scores in two groups were significantly increased(P < 0.05),but NIH-CPSI scores were significantly decreased(P < 0.05), and these scores in the treatment group were significantly better than those in the control group(P < 0.05). After treatment, the maximum urine flow rate and average urinary flow rate in two groups was significantly increased(P < 0.05), and which in the treatment group was significantly higher than that in the control group(P < 0.05).After treatment, the IL-2, IL-6, MIP-2 and CTGF levels of prostatic fluid in two groups were significantly decreased(P < 0.05), but TGF-β1 levels were significantly decreased(P < 0.05), and these cytokine levels of prostatic fluid in the treatment group were significantly better than those in the control group(P < 0.05). Conclusion Danyi Tablets combined with Prostat Tablets in treatment of chronic nonbacterial prostatitis can significantly improve the cytokine levels and the clinical symptoms of patients, increase the urine flow rate.
引文
[1]那彦群.中国泌尿外科疾病诊断治疗指南[M].北京:人民卫生出版社,2007:205-243.
[2]张春雷,刘成.慢性非细菌型前列腺炎治疗的相关进展[J].中国医药导报,2015,12(10):38-42.
[3]李伟,冯勇,王福利.前列倍喜胶囊联合普适泰片治疗前列腺增生的疗效观察[J].现代药物与临床,2017,32(10):1955-1958.
[4]杨丽娟,陆金梅,王玉英,等.丹益片治疗慢性非细菌性前列腺炎的疗效观察[J].中国临床研究,2014,27(8):990-991.
[5]吴阶平.吴阶平泌尿外科学[M].济南:山东科学技术出版社,2004:584-586.
[6]郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:171-172.
[7]庄申榕,马洪铭,潘天明,等.120例前列腺增生患者国际勃起功能指数-5(IIEF-5)调查报告[J].老年医学与保健,2001,7(4):242-243.
[8]张春,李惠长,钱本江,等.慢性前列腺炎患者SDS、SAS与NIH-CPSI评分的相关性分析及综合治疗评价[J].中国医学创新,2012,9(8):1-3.
[9]黄立华.治疗前后CAP患者前列腺液和血清中IL-1β、IL-2、IL-10检测的临床意义[J].现代医药卫生,2010,26(13):1954-1956.
[10]王成荣,卞廷松,史兵伟,等.慢性非细菌性前列腺炎患者前列腺液中IL-6和IL-22水平的研究[J].海南医学,2014,25(22):3314-3316.
[11]王云鹏,李文平,马玉国,等.慢性前列腺炎患者前列腺液中MIP-2、iNOS的表达及意义[J].山东医药,2007,47(36):103-104.
[12]李永伟,王春霞,何志强.TNF-α、TGF-β1在慢性非细菌性前列腺炎病人前列腺液中的表达水平及意义[J].中国老年学杂志,2013,33(14):3409-3410.
[13]邝世航,黄双艺,乐有为,等.慢性前列腺炎TGF-β1、CTGF的表达水平及其与症状指数的关系[J].中华腔镜泌尿外科杂志:电子版,2018,12(2):125-128.
[2]张春雷,刘成.慢性非细菌型前列腺炎治疗的相关进展[J].中国医药导报,2015,12(10):38-42.
[3]李伟,冯勇,王福利.前列倍喜胶囊联合普适泰片治疗前列腺增生的疗效观察[J].现代药物与临床,2017,32(10):1955-1958.
[4]杨丽娟,陆金梅,王玉英,等.丹益片治疗慢性非细菌性前列腺炎的疗效观察[J].中国临床研究,2014,27(8):990-991.
[5]吴阶平.吴阶平泌尿外科学[M].济南:山东科学技术出版社,2004:584-586.
[6]郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:171-172.
[7]庄申榕,马洪铭,潘天明,等.120例前列腺增生患者国际勃起功能指数-5(IIEF-5)调查报告[J].老年医学与保健,2001,7(4):242-243.
[8]张春,李惠长,钱本江,等.慢性前列腺炎患者SDS、SAS与NIH-CPSI评分的相关性分析及综合治疗评价[J].中国医学创新,2012,9(8):1-3.
[9]黄立华.治疗前后CAP患者前列腺液和血清中IL-1β、IL-2、IL-10检测的临床意义[J].现代医药卫生,2010,26(13):1954-1956.
[10]王成荣,卞廷松,史兵伟,等.慢性非细菌性前列腺炎患者前列腺液中IL-6和IL-22水平的研究[J].海南医学,2014,25(22):3314-3316.
[11]王云鹏,李文平,马玉国,等.慢性前列腺炎患者前列腺液中MIP-2、iNOS的表达及意义[J].山东医药,2007,47(36):103-104.
[12]李永伟,王春霞,何志强.TNF-α、TGF-β1在慢性非细菌性前列腺炎病人前列腺液中的表达水平及意义[J].中国老年学杂志,2013,33(14):3409-3410.
[13]邝世航,黄双艺,乐有为,等.慢性前列腺炎TGF-β1、CTGF的表达水平及其与症状指数的关系[J].中华腔镜泌尿外科杂志:电子版,2018,12(2):125-128.